Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Summary not available.
Vizgen has appointed Dale Levitzke as Senior Vice President of Global Sales and Support, aiming to enhance its commercial reach for the MERSCOPE Platform.
Levitzke, with nearly 20 years in diagnostics sales, previously led NanoString's revenue growth from under $10MM to over $125MM. His experience will help Vizgen navigate the global market and expand distribution channels in 2022.
The MERSCOPE Platform offers significant insights into spatial genomics, with early uptake at leading institutions, reflecting strong demand in the burgeoning field of spatial biology.
Illumina has appointed Bob Ragusa as the new CEO of GRAIL, effective immediately, focusing on multi-cancer early detection. Ragusa, with over 30 years in genomics and previously Illumina's COO, aims to scale GRAIL and enhance its cancer detection test, Galleri. He takes over from Hans Bishop, who steps down after leading GRAIL since June 2019 and will continue as an advisor until the end of 2021. Illumina emphasizes Ragusa's track record in operational excellence, aiming for growth and innovation in cancer diagnostics.
Illumina, Inc. (NASDAQ:ILMN) will release its third quarter 2021 financial results on November 4, 2021, after market close. A conference call with CEO Francis deSouza and CFO Sam Samad is scheduled for the same day at 2:00 PM PT (5:00 PM ET) to discuss the results. Participants can access the call via Illumina's website or by dialing the provided numbers. A replay will be available for 30 days. Illumina continues to lead in DNA sequencing and genomics, serving various markets including life sciences and oncology.
Illumina (NASDAQ: ILMN) has established two new entities, Illumina Colombia S.A.S. and Illumina México Productos de Biotecnología, to enhance genomics support in Latin America. This initiative follows significant investment and growth in the region. General Manager Nicole Berry emphasized Colombia’s status as South America’s second-largest country and highlighted Mexico as a key market for Illumina. These entities aim to advance clinical services in local healthcare systems, ensuring customers receive optimal training and support for their genomic instruments.
Illumina (NASDAQ: ILMN) has announced findings from the NICUSeq Randomized Time-Delayed Trial, indicating that clinical whole-genome sequencing (cWGS) is twice as effective as usual care in diagnosing acutely ill newborns suspected of genetic conditions. The study involved 354 infants and demonstrated that access to cWGS significantly enhanced diagnostic rates and clinical management decisions. The trial's results advocate for broader implementation of cWGS, suggesting it may become a first-tier diagnostic tool for critically ill infants, thereby improving patient outcomes and healthcare strategies.
Illumina Ventures has closed its second investment fund, raising $325 million to enhance its capital to $560 million. The fund, primarily backed by Illumina, Inc. (NASDAQ: ILMN), aims to invest in innovative start-ups in healthcare, particularly in genomics and precision medicine. Since its inception in 2016, Illumina Ventures has invested in 25 companies, contributing to life science advancements. The firm plans to explore more ambitious projects in the US and Europe, reflecting its commitment to transforming healthcare.
Illumina has selected seven genomics startups for its third global funding cycle of the Illumina Accelerator, demonstrating a strong international presence with investments in companies from six countries. The selected startups include BIXBIO LIMITED, EpiCombi.AI Limited, Genegoggle Sp. z o.o., and NewStem Ltd. from Cambridge, and ImYoo Inc., Solena Ag, Inc., and Yali Biosciences Inc. from the SF Bay Area. Illumina aims to boost innovation in genomics by providing seed investment, tech access, and expert guidance.
Illumina (NASDAQ: ILMN) has announced its commitment to achieving net-zero greenhouse gas emissions by 2050, aligning with the Paris Agreement. The company has set science-based targets for emission reductions of 46% from direct and indirect operations by 2030. This initiative signifies a shift from prior climate goals based on a 2°C warming scenario to more rigorous 1.5°C guidelines. Additionally, Illumina has pledged $20 million by 2030 towards sustainability initiatives. These moves underscore the company's dedication to corporate social responsibility and the integration of sustainability into its business strategy.
Illumina has partnered with Merck to develop tests identifying genetic mutations for assessing homologous recombination deficiency (HRD), enhancing patient access to targeted PARP inhibitor treatments. This collaboration expands upon prior work with Myriad Genetics to offer a new HRD companion diagnostic test for ovarian cancer patients in the EU and UK. Illumina will also create a research-use only HRD assay for global distribution. This initiative reflects Illumina's commitment to advancing precision medicine and improving patient outcomes through innovative genomic profiling.